|
 |
Article Review/Hyperlink
|
Packer M
ACC Press Release: Beta blocker reduces hospitalizations in
patients with the most advances chronic heart failure
Am Coll Cardiol PR
(Mar) 21:Web, 2001

The following press release was issued by the American College of Cardiology concerning a
paper presented at the March 2001 Annual Meeting:
(ORLANDO, FLA.)_Treatment with the beta blocker carvedilol significantly
reduced the risk of hospitalization in patients
with the most advanced form of chronic heart failure in the "Carvedilol
Prospective Randomized Cumulative Survival"
trial (COPERNICUS).
COPERNICUS investigators last year reported that carvedilol was associated
with a significant 35 percent decline in the
risk of death in their patients with such advanced, so-called New York Heart
Association class IV heart failure. But, in
addition, "We found a rather dramatic reduction in the risk of
hospitalization, which was true regardless of whether we
looked at hospitalization for any reason, for only heart failure or for any
other cardiovascular cause," said Dr. Milton
Packer, of Columbia University College of Physicians and Surgeons, New York
City.
COPERNICUS patients had the most advanced stable heart failure ever studied
in a beta blocker trial, Dr. Packer
observed. He is scheduled to present the trial's results on hospitalizations,
clinical outcomes, and drug safety at 9
a.m. on Tuesday, March 20, at the American College of Cardiology 50th Annual
Scientific Session in Orlando, Fla.
Related Folders: |
 |
|
|
|
|